Lymphoma Combination Therapy Failed to Extend Survival
A new clinical trial found that adding lenalidomide to rituximab did not significantly improve outcomes for patients.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you believe the potential health benefits of combination therapies outweigh the risk of side effects?
A phase 3 clinical trial of 152 patients with relapsed or refractory follicular lymphoma found that adding lenalidomide to rituximab maintenance did not result in a statistically significant improvement in 2-year progression-free survival compared to rituximab alone.
Why it matters
Researchers investigated this combination to see if lenalidomide could enhance standard maintenance therapy, but the findings suggest the approach may not provide the intended benefit for older patients.
In a phase 3 trial of 152 patients with a median age of 71, investigators compared rituximab monotherapy against a combination regimen. The combination showed no statistically significant improvement in 2-year progression-free survival, though researchers noted potential benefits for younger subgroups.
The players
Blood Advances
A peer-reviewed hematology journal that publishes clinical and translational research findings.
The details
Patients in the monotherapy group received rituximab every 90 days for eight cycles. Those in the combination group added lenalidomide, taken on days 1-21 of a 28-day cycle for 24 cycles. The combination arm experienced higher rates of grade 3/4 adverse events, specifically neutropenia, which occurred in 40.6% of patients compared to 11.5% in the monotherapy group.
Timeline
September 21, 2026: Study results published online in Blood Advances.
Health Landscape
This trial evaluates the evolution of rituximab maintenance therapy for follicular lymphoma by testing it against more aggressive combination regimens. The results highlight the ongoing challenge of balancing efficacy with treatment toxicity in older patient populations.
Patients and caregivers should discuss these findings with an oncologist to understand how they influence treatment options for relapsed follicular lymphoma. Given the high rate of neutropenia observed in the combination arm, it is important to review potential side effects with your medical team.
The takeaway
This trial indicates that adding lenalidomide to rituximab does not offer a statistically significant survival benefit for patients with relapsed or refractory follicular lymphoma. Patients should focus on monitoring for treatment-related side effects like neutropenia during maintenance therapy.
Further reading
For broader context on current clinical research, visit the Cancer section of our site.
Source note: This article includes information reported by Medscape.
Live Poll
Do you believe the potential health benefits of combination therapies outweigh the risk of side effects?
